ATP1A3 Alternating Hemiplegia of Childhood — designated AHC, ATP1A3-Related Neurological Disorder, CAPOS Syndrome, and Rapid-Onset Dystonia-Parkinsonism (RDP), a spectrum of autosomal dominant neurological disorders caused by heterozygous de novo gain-of-function or dominant-negative pathogenic variants in ATP1A3 (ATPase Na+/K+ transporting subunit alpha 3 gene, chromosome 19q13); ATP1A3 encodes the alpha-3 catalytic subunit of the Na+/K+-ATPase (sodium-potassium pump) — the transmembrane ion pump that is the primary mechanism for maintaining the electrochemical gradient across neuronal membranes; the pump expels 3 Na+ ions in exchange for 2 K+ ions per ATP hydrolysis cycle, establishing the resting membrane potential that is fundamental to neuronal excitability, signal propagation, and cellular volume regulation; the alpha-3 subunit is expressed predominantly in neurons (distinguishing it from alpha-1, which is ubiquitous), making ATP1A3 variants selectively neurotoxic; specific phenotype-genotype correlations define the ATP1A3 disorder spectrum: (1) Alternating Hemiplegia of Childhood (AHC — D801N, E815K variants) — episodes of hemiplegia (alternating left and right), tonic and dystonic attacks, oculomotor abnormalities (nystagmus, strabismus), autonomic features (flushing, diaphoresis, apnea), and epilepsy; episodes triggered by bathing, temperature changes, physical activity, and excitement; episodes pathognomically resolve with sleep; chronic progressive cognitive and motor decline accumulates with episode burden; (2) Rapid-Onset Dystonia-Parkinsonism (RDP — G947R and other variants) — acute onset of generalized dystonia with parkinsonian features triggered by physiological stress; (3) CAPOS Syndrome (Cerebellar Ataxia, Areflexia, Pes Cavus, Optic Atrophy, Sensorineural hearing loss — E818K variant) — as one of the most demanding rare disease care management challenges in pediatric neurology, requiring 24-hour caregiver supervision, detailed episode diary documentation, and meticulous trigger avoidance.
ATP1A3 AHC care technology platforms — encompassing the molecular genetics laboratories where ATP1A3 sequencing and functional characterization confirm the diagnosis and identify the specific variant driving the AHC, RDP, or CAPOS phenotype; the episode diary systems that are the primary outcome measure and treatment response indicator for AHC — the attack frequency tracking portals, laterality and duration recording tools, trigger diary systems, and severity scoring platforms that accumulate the longitudinal episode data used to evaluate flunarizine response, guide benzodiazepine rescue thresholds, and identify individual trigger patterns for avoidance; the trigger avoidance documentation platforms coordinating the bathing temperature protocols, activity limitation schedules, and environmental modification records that are the primary non-pharmacological AHC intervention; the flunarizine adherence and dose titration portals managing the primary AHC pharmacotherapy; the benzodiazepine rescue coordination platforms managing the prolonged episode rescue protocols and caregiver administration training records; the aquatherapy and bathing safety protocol systems that document the supervised lukewarm bathing protocols required because water is a recognized AHC trigger; and the ophthalmology surveillance scheduling tools and neurocognitive assessment platforms managing the oculomotor and cognitive monitoring requirements of chronic AHC — must maintain availability and performance standards matched to the episode management urgency, trigger avoidance safety requirements, and 24-hour caregiver burden of modern AHC care. This guide explains why ATP1A3 AHC care tech platforms need dedicated monitoring, what to monitor, and how to build a monitoring strategy matched to the episode diary urgency and aquatherapy safety protocol requirements of contemporary AHC management.
Why ATP1A3 AHC Tech Platforms Require Specialized Monitoring Attention
ATP1A3 AHC management is defined by several clinically urgent platform requirements: the episode diary urgency — the AHC episode diary is the primary outcome measure, treatment response indicator, and trigger identification tool; episode diary platform availability at the moment an episode begins determines whether the attack duration, laterality, trigger, and autonomic features are documented in real-time rather than reconstructed from memory, directly affecting the clinical quality of the longitudinal dataset that drives flunarizine dose adjustment and trigger avoidance protocol refinement; the aquatherapy and bathing safety urgency — water and temperature change are potent AHC triggers, and the supervised bathing protocol documentation platform availability ensures that caregivers, respite workers, school staff, and hospital nursing staff follow the specific temperature and supervision protocols that prevent bath-induced AHC episodes; the rescue medication urgency — prolonged AHC episodes require diazepam rectal or midazolam buccal rescue, and the caregiver training records and rescue thresholds must be accessible at any location including emergency encounters; the trigger avoidance urgency — AHC is triggered by bathing, temperature change, physical activity, emotional excitement, and illness, and the individual trigger profile documented in the platform determines which activities require modification, which require supervision, and which require complete avoidance; the 24-hour supervision urgency — AHC requires continuous caregiver supervision, and the platform availability for schedule coordination, respite care handover, and carer burden monitoring directly affects the sustainability of the care system.
Molecular genetic testing platforms confirm ATP1A3 variant and AHC/RDP/CAPOS subtype. ATP1A3 sequencing distinguishes AHC-causing D801N and E815K from RDP-causing G947R and CAPOS-causing E818K variants with distinct management implications. Monitor at 1-minute intervals during laboratory hours.
Episode diary and attack tracking platforms capture the primary AHC outcome measure. Real-time episode documentation — laterality, duration, trigger, severity, sleep resolution — drives flunarizine dose titration and trigger avoidance protocol refinement. Monitor at 1-minute intervals, 24/7.
Aquatherapy and bathing safety protocol platforms coordinate the supervised water exposure protocols. Temperature-controlled bathing documentation and supervision records prevent bath-induced AHC episodes across home, respite, school, and hospital settings. Monitor at 1-minute intervals during clinical hours.
Flunarizine adherence and dose titration portals manage the primary AHC pharmacotherapy. Weight-based dosing, dose titration records, and flunarizine response correlation with episode frequency drive treatment optimization. Monitor at 1-minute intervals during clinical hours.
Benzodiazepine rescue coordination platforms manage prolonged episode rescue protocols. Diazepam and midazolam rescue records, caregiver training, and administration event documentation require platform availability at emergency encounters. Monitor at 1-minute intervals during clinical hours.
What to Monitor on an ATP1A3 AHC Care Tech Platform
Molecular Genetic Testing — ATP1A3 Variant Characterization and Phenotype Subtyping
Monitor ATP1A3 gene sequencing records (full coding sequence analysis — D801N and E815K variant identification for AHC phenotype; G947R and other variant characterization for RDP phenotype; E818K characterization for CAPOS syndrome; additional AHC-associated variant documentation — G947D, L864P, and others; ACMG variant classification; de novo confirmation via trio analysis; parental testing records; hotspot variant rapid sequencing records for expedited diagnosis in classic AHC presentation), phenotype-genotype correlation records (AHC severity correlation with D801N vs. E815K — E815K associated with more severe phenotype in published literature; CAPOS syndrome multimodal assessment records — cerebellar, auditory, ophthalmic, reflexology, podiatric records; RDP acute onset documentation — stress trigger characterization; functional Na+/K+-ATPase pump activity assay records where available), and genetic counseling records (de novo recurrence risk counseling — <1% recurrence risk for subsequent pregnancies after de novo event; autosomal dominant transmission risk — 50% offspring risk if parent affected; phenotype severity counseling; trigger avoidance rationale based on sodium-potassium pump failure mechanism; AHC advocacy organization referral — Alternating Hemiplegia of Childhood Foundation; natural history registry enrollment — AHC Foundation research database) at 1-minute intervals during laboratory hours. Alert immediately — ATP1A3 molecular testing platform failures during evaluation of a 7-month-old male with recurrent episodes of right arm and leg weakness lasting 2–6 hours that resolve completely with sleep, nystagmus, and two dystonic episodes with flushing and diaphoresis — when ATP1A3 sequencing identifying the D801N variant confirms AHC, initiates flunarizine prescription and dose titration, establishes the episode diary as the primary outcome measure, prompts the critical trigger avoidance counseling including the aquatherapy warning, enables AHC Foundation registry enrollment, and prevents the months of diagnostic odyssey through CADASIL, hemiplegic migraine, mitochondrial disease, and stroke evaluation that typically precede AHC diagnosis without molecular confirmation.
Episode Diary and Attack Documentation — Primary AHC Outcome Measure
Monitor real-time episode diary records (episode onset date and time documentation; episode duration — onset to resolution or sleep; episode laterality — right hemiplegia, left hemiplegia, bilateral involvement; motor features — flaccid vs. dystonic hemiplegia; tonic/dystonic attack documentation separate from hemiplegic episodes; autonomic feature documentation — flushing, diaphoresis, pallor, apnea, pupillary changes; oculomotor feature documentation — nystagmus type and direction, strabismus; language and cognition during episode — speech preservation, consciousness level; sleep termination confirmation — resolution with sleep is pathognomonic; duration to full recovery post-sleep), episode trigger documentation records (bathing trigger — water temperature documented; temperature change trigger — hot or cold; physical activity trigger — type, intensity, duration; emotional excitement trigger — positive or negative; illness trigger — fever, viral illness; flickering light documentation; hunger and hypoglycemia documentation; specific personal trigger pattern documentation — individual AHC trigger profile; trigger identification trend analysis records), flunarizine dose-response correlation records (episode frequency trend on current flunarizine dose vs. pre-treatment baseline; breakthrough episode characterization on optimized flunarizine dose; episode severity trend on flunarizine — duration, functional impact; flunarizine response classification — >50% reduction, >75% reduction; alternative treatment response records — amantadine, memantine records for non-responders), and inter-episode functional assessment records (inter-episode neurological status documentation — baseline motor function, gait, coordination; chronic motor deficit accumulation records — cumulative hemiplegia burden; cognitive function trend between episodes; behavioral status inter-ictally) at 1-minute intervals, 24/7. Alert immediately — episode diary platform failures preventing a caregiver from documenting the onset, laterality, trigger, and autonomic features of a 4-hour right hemiplegic episode in a 4-year-old AHC female who began the episode while at the swimming pool — when the episode diary is the platform through which the treating neurologist will later determine that water exposure at the swimming pool initiated a right-sided hemiplegic episode with associated nystagmus and diaphoresis lasting 4 hours before resolving with a nap in the car, identifying water immersion as a personal primary trigger for this child and prompting the aquatherapy safety protocol update restricting pool exposure to supervised shallow wading with close caregiver monitoring rather than full swimming lesson participation.
Trigger Avoidance Documentation — Safety Protocol Management
Monitor trigger avoidance protocol records (individual trigger profile documentation — bathing, temperature, activity, excitement, illness triggers identified for each AHC patient; temperature threshold documentation for trigger avoidance — warm vs. hot water; lukewarm bathing protocol records; shower-only vs. bath records where bathing is more triggering; trigger avoidance update records — trigger profile evolution with age), aquatherapy and bathing safety protocol records (supervised bathing protocol documentation — caregiver presence requirement, temperature specified, duration limit; bath temperature monitoring protocol — thermometer use documentation; shower substitution protocol where bath triggers episodes; pool and swimming safety protocol — supervised shallow wading, avoidance of submersion; hydrotherapy for physiotherapy — modified safety protocol for aquatic physiotherapy; beach and recreational water safety protocol; WATER IS A TRIGGER documentation — conspicuous safety alert visible to new caregivers), activity modification records (physical activity level limitation documentation — trigger-threshold activity intensity; emotional excitement management protocol; school physical education modification records; party and social event overstimulation management protocol; travel and change-in-routine protocol), and environmental trigger management records (temperature-controlled home environment records; car travel temperature management; hot weather protocol; illness fever management to prevent illness-triggered episodes; holiday and environmental change preparation protocol) at 1-minute intervals during clinical hours.
Flunarizine Adherence and Dose Titration — Primary AHC Pharmacotherapy
Monitor flunarizine prescription and adherence records (flunarizine dose records — dose in mg/kg, total daily dose, twice-daily splitting; dose titration records — initial dose, titration schedule, target dose; adherence records — medication administration log; pharmacy refill records; weight-based dose recalculation records as child grows; flunarizine supply records), flunarizine dose-response and monitoring records (episode frequency trend on current dose; dose escalation decision records; dose reduction records for adverse effects; flunarizine adverse effect monitoring — sedation assessment, weight gain monitoring, extrapyramidal sign monitoring, depression screening in adolescents; drug holiday records — scheduled flunarizine holidays where used; QTc interval monitoring records where indicated), and non-responder and adjunct treatment records (amantadine response records for flunarizine non-responders; memantine trial records; nimodipine trial records; carbamazepine records for dystonic attack component; adenosine pathway intervention records; ketogenic diet records for AHC-associated epilepsy component) at 1-minute intervals during clinical hours.
Benzodiazepine Rescue Coordination — Prolonged Episode Management
Monitor rescue medication prescription and supply records (rectal diazepam prescription records — dose, concentration, device; buccal midazolam prescription records — dose, volume, administration device; rescue medication supply verification records — home, school, respite location; expiry date tracking and replacement scheduling; pharmacy refill records), caregiver rescue medication training records (rectal diazepam administration training completion — dose, device technique, duration threshold for administration; buccal midazolam training records; multi-carer training — parents, school nurse, respite carer, grandparents; competency assessment and refresher training records), rescue administration event records (rescue medication administration date, time, duration of episode at administration; dose administered; time to episode resolution; effectiveness documentation; emergency services contact records; emergency department records for rescue-refractory prolonged episodes; post-rescue recovery documentation), and rescue threshold decision records (episode duration threshold for rescue administration — neurologist-specified threshold; prolonged dystonic attack rescue threshold; status hemiplegicus management records; episode management protocol version history) at 1-minute intervals during clinical hours.
Epilepsy Co-Management — AHC-Associated Seizure Monitoring
Monitor AED adherence and seizure diary records (AHC-associated epilepsy AED prescription records — valproate, clobazam, levetiracetam; drug level monitoring records; seizure diary records separate from hemiplegic episode diary — tonic-clonic, myoclonic, absence seizure documentation; seizure frequency trend on current AED regimen; rescue medication records for prolonged seizures; EEG scheduling and result records for AHC-associated epilepsy), and AHC episode vs. seizure differentiation records (clinical differentiation documentation — EEG-confirmed ictal vs. AHC episode records; video-EEG records where episode vs. seizure differentiation required; combined AHC episode and seizure event documentation) at 1-minute intervals during clinical hours.
Oculomotor Surveillance and Neurocognitive Assessment
Monitor ophthalmology surveillance records (annual ophthalmology review scheduling and results — nystagmus type and severity documentation; strabismus assessment and surgery records; visual acuity monitoring; amblyopia screening; optic atrophy records for CAPOS syndrome subtype; sensorineural hearing loss surveillance records for CAPOS), and neurocognitive assessment records (annual neuropsychological assessment — cognitive trajectory in chronic AHC; attention and executive function assessment; language assessment; academic achievement testing; IEP coordination records; progressive cognitive decline documentation — cumulative episode burden correlation; behavioral assessment records) at 1-minute intervals during clinical hours.
Physiotherapy and Carer Psychosocial Support
Monitor inter-episode physiotherapy records (physiotherapy scheduling and session records — inter-episode motor rehabilitation for accumulated motor deficit; gait training and spasticity management records; adaptive equipment prescription — AFO, walker, wheelchair; PT home exercise program records; school physical education adaptation records), and carer burden and psychosocial support records (carer burden assessment records — burnout screening; psychosocial support services coordination; respite care scheduling and caregiver handover records; AHC Foundation family community records; sibling support records; 24-hour supervision schedule documentation — shift sharing between parents) at 1-minute intervals during clinical hours.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. AHC management requires round-the-clock carer access to episode diaries, trigger protocols, rescue medication records, and bathing safety protocols — authentication failures during a nighttime hemiplegic episode or bathing preparation create direct patient safety risk.
SSL Certificates
Monitor SSL certificate expiry across all molecular testing platforms, episode diary portals, trigger avoidance documentation systems, flunarizine monitoring tools, and rescue medication training platforms. Certificate errors disrupting the aquatherapy safety protocol portal before a supervised bathing session remove the documentation safeguard that prevents bath-induced AHC episode triggers.
HIPAA and Rare Disease Privacy Considerations for ATP1A3 AHC
ATP1A3 AHC technology platforms handle molecular genetic records (ATP1A3 pathogenic variant, de novo mutation, family genetic implications), episode diary records with trigger documentation (bathing, emotional, and activity trigger data — intimate behavioral records), aquatherapy safety protocol records (home bathing supervision documentation), flunarizine prescription and dose records, benzodiazepine rescue administration records with emergency event documentation, oculomotor and ophthalmology surveillance records, annual neuropsychological assessment records, carer burden and psychosocial support records, and 24-hour supervision schedule records across affected children and their families.
Alerting Strategy for ATP1A3 AHC Tech Platforms
Immediate laboratory-hours alerting for molecular genetic testing platforms: ATP1A3 variant characterization — the diagnosis initiating episode diary monitoring, flunarizine prescription, and trigger avoidance protocols.
Immediate 24/7 alerting for episode diary and attack tracking platforms: Real-time hemiplegic episode documentation — the primary AHC outcome measure driving treatment decisions at any hour.
Immediate 24/7 alerting for trigger avoidance and aquatherapy safety documentation platforms: Bathing safety protocols accessible to caregivers, respite workers, school staff, and hospital nurses — patient safety requirements.
Immediate clinical-hours alerting for flunarizine adherence and dose titration portals: Primary pharmacotherapy monitoring and dose-response correlation.
Immediate clinical-hours alerting for benzodiazepine rescue coordination platforms: Prolonged episode rescue threshold, caregiver training records, and administration event documentation.
Immediate clinical-hours alerting for epilepsy co-management portals: AHC-associated seizure diary, AED monitoring, and EEG scheduling.
Immediate clinical-hours alerting for oculomotor and neurocognitive assessment scheduling: Annual ophthalmology and neuropsychological review.
Sustained-failure alert (10–15 minutes): Physiotherapy coordination and carer psychosocial support records.
30-day advance warning: SSL certificates across all platforms.
Status Page for ATP1A3 AHC Care Team Communication
A real-time status page gives molecular genetics laboratories, pediatric neurologists and AHC specialists, ophthalmologists, physiotherapists, occupational therapists, neuropsychologists, respite care coordinators, school nurses, emergency medicine physicians, and rare disease registry coordinators immediate platform visibility without requiring inbound IT support contact at any hour.
Vigilmon Setup for ATP1A3 AHC Tech Platforms
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | ATP1A3 molecular testing and variant characterization | 1 min | Slack + PagerDuty (lab hours) | | Genetic counseling and AHC Foundation enrollment records | 1 min | Slack + PagerDuty (lab hours) | | Episode diary and attack laterality tracking portal | 1 min | Slack + PagerDuty (24/7) | | Trigger diary and individual trigger profile records | 1 min | Slack + PagerDuty (24/7) | | Aquatherapy and bathing safety protocol documentation | 1 min | Slack + PagerDuty (24/7) | | Flunarizine prescription and adherence records | 1 min | Slack + PagerDuty (clinical hours) | | Flunarizine dose-response correlation and titration records | 1 min | Slack + PagerDuty (clinical hours) | | Benzodiazepine rescue prescription and supply records | 1 min | Slack + PagerDuty (clinical hours) | | Caregiver rescue medication training and competency records | 1 min | Slack + PagerDuty (clinical hours) | | Rescue medication administration event records | 1 min | Slack + PagerDuty (clinical hours) | | AHC-associated epilepsy AED monitoring and seizure diary | 1 min | Slack + PagerDuty (clinical hours) | | Annual ophthalmology surveillance scheduling | 1 min | Slack + PagerDuty (clinical hours) | | Annual neuropsychological assessment scheduling | 1 min | Slack + PagerDuty (clinical hours) | | Inter-episode physiotherapy and adaptive equipment records | 2 min | Slack (business hours) | | Carer burden assessment and respite coordination records | 2 min | Slack (business hours) | | AHC Foundation natural history registry records | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure ATP1A3 molecular testing platforms with immediate laboratory-hours alerting
- Add episode diary and attack laterality tracking portal at 1-minute intervals with 24/7 alerting — real-time episode documentation is the primary AHC outcome measure at any hour
- Configure trigger diary and individual trigger profile records with 24/7 alerting — trigger identification drives the non-pharmacological AHC management
- Add aquatherapy and bathing safety protocol documentation with 24/7 alerting — water trigger safety protocols must be accessible to caregivers, respite workers, and hospital staff at any hour
- Configure flunarizine prescription and adherence records with immediate clinical-hours alerting — primary AHC pharmacotherapy monitoring
- Add flunarizine dose-response correlation records with immediate clinical-hours alerting — treatment response assessment drives dose titration
- Configure benzodiazepine rescue prescription and supply records with immediate clinical-hours alerting
- Add caregiver rescue medication training records with immediate clinical-hours alerting — competency documentation for all carers managing prolonged AHC episodes
- Configure rescue medication administration event records with immediate clinical-hours alerting
- Add AHC-associated epilepsy AED monitoring and seizure diary with immediate clinical-hours alerting
- Configure annual ophthalmology and neuropsychological assessment scheduling with immediate clinical-hours alerting
- Add physiotherapy and respite coordination records with sustained-failure business-hours alerting
- Enable SSL certificate monitoring across all platforms — aquatherapy safety protocol portal SSL failure before a bathing session creates direct patient safety risk
- Add the status page URL to AHC neurology downtime protocols, episode rescue emergency procedures, and school and respite care AHC management workflows
Conclusion
ATP1A3 Alternating Hemiplegia of Childhood technology platforms are embedded in clinical decisions where episode diary platform availability at the poolside — when the caregiver of a 5-year-old AHC male attempts to enter the episode onset time, trigger (pool entry), and initial laterality (right arm weakness) in real time using the mobile portal on her phone, and the platform is unreachable due to a regional outage, so the episode is not documented until 3 hours later from memory with inexact duration and trigger details — cannot be disrupted by episode diary platform failures that compromise the temporal precision and trigger correlation of the primary clinical outcome measure; the difference between "pool entry triggered a right hemiplegic episode lasting 4 hours" documented in real time and "we think he had an episode at the pool, maybe 3–4 hours, right side" reconstructed from memory 3 hours later is the difference between a trigger correlation analysis that identifies swimming pool immersion as a personal AHC trigger requiring protocol modification and a diary entry too imprecise to distinguish pool water trigger from excitement trigger from exercise trigger — distinctions that determine whether the management response is aquatherapy restriction, emotional regulation support, or physical activity modification; where aquatherapy safety protocol platform availability at hospital admission — when the nursing staff on the general pediatric ward admitting a 6-year-old AHC female for a respiratory infection attempt to plan her evening bathing routine without access to her AHC care plan, which is unreachable due to a platform certificate error, and proceed with a standard bath at ward temperature (38°C water) for 15 minutes — cannot be disrupted by care plan platform failures that remove the documented protocol specifying that this patient's AHC episodes are consistently triggered by warm bath water above 35°C, that showers at body temperature or below are the safe alternative, and that any bathing requires direct adult supervision and a 5-minute maximum exposure, making the platform availability at the moment the ward nurse fills the bath the determinant of whether a preventable bath-triggered hemiplegic episode occurs during a hospital admission for an unrelated respiratory illness; and where molecular testing platform availability during the diagnostic evaluation — when ATP1A3 sequencing confirming the D801N variant in a 9-month-old with recurrent alternating hemiplegia terminates the diagnostic odyssey, initiates flunarizine and establishes the episode diary as the outcome measure, provides the caregiver with the trigger avoidance framework including the critical water trigger warning, connects the family to the AHC Foundation before they spend another six months without a diagnosis navigating hemiplegic episodes without management infrastructure — cannot be disrupted by molecular testing platform failures that delay a diagnosis whose consequences for care infrastructure establishment are as significant as its genetic content.
Uptime monitoring gives ATP1A3 AHC care tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to molecular genetics laboratories, pediatric neurologists and AHC specialists, ophthalmologists, physiotherapists, neuropsychologists, respite care coordinators, school nurses, emergency medicine physicians, rare disease registry coordinators, and compliance auditors that platform operational reliability matches the episode diary urgency, aquatherapy safety requirements, 24-hour caregiver supervision demands, and rescue medication safety requirements of modern AHC management.
Start monitoring your ATP1A3 AHC care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #ATP1A3 #alternatinghemiplegia #AHC #hemiplegia #sodiumPotassiumATPase #NaKpump #flunarizine #episodediary #triggerdiary #aquatherapy #bathingsafety #diazepamrescue #midazolam #CAPOS #RDP #dystonia #parkinsonism #oculomotor #nystagmus #strabismus #raredisease #channelopathy #neurology #HIPAA #healthtech #digitalhealth #uptime #sre